Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study
Objective. To describe our institution’s experience with the AngioVac system. Background. Intracardiac and intravascular masses previously required surgical excision, but now, there are a number of minimally invasive options. With the advent of vacuum aspiration, more specifically the AngioVac Syste...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Interventional Cardiology |
| Online Access: | http://dx.doi.org/10.1155/2021/9923440 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561353458450432 |
|---|---|
| author | Aashish Katapadi Lauren Richards William Fischer Suhail Q. Allaqaband Tanvir Bajwa M. Fuad Jan |
| author_facet | Aashish Katapadi Lauren Richards William Fischer Suhail Q. Allaqaband Tanvir Bajwa M. Fuad Jan |
| author_sort | Aashish Katapadi |
| collection | DOAJ |
| description | Objective. To describe our institution’s experience with the AngioVac system. Background. Intracardiac and intravascular masses previously required surgical excision, but now, there are a number of minimally invasive options. With the advent of vacuum aspiration, more specifically the AngioVac System (AngioDynamics, NY, USA), there exists a system with both low mortality and minor complications. However, the number of retrospective studies remains limited. Outcome data for high-risk patients are also limited. Methods. Data were collected and analyzed in patients who underwent AngioVac therapy at our tertiary care center from January 2014 to December 2020. Results. Our results demonstrated a 93.3% intraoperative success rate and a 100% intraoperative survival rate. However, a number of complications, including but not limited to hematomas, anemia, and hypotension, occurred, as described below. Conclusions. Our experiences demonstrated good outcomes and continue to support the usefulness of the AngioVac System. The data also support the use of AngioVac as a treatment option for the debulking or removal of right heart masses in critically ill patients. |
| format | Article |
| id | doaj-art-50cfedfc9d3642d6aac09563bc8fc1f4 |
| institution | Kabale University |
| issn | 1540-8183 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Interventional Cardiology |
| spelling | doaj-art-50cfedfc9d3642d6aac09563bc8fc1f42025-02-03T01:25:14ZengWileyJournal of Interventional Cardiology1540-81832021-01-01202110.1155/2021/9923440Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational StudyAashish Katapadi0Lauren Richards1William Fischer2Suhail Q. Allaqaband3Tanvir Bajwa4M. Fuad Jan5Aurora Cardiovascular and Thoracic ServicesAurora Cardiovascular and Thoracic ServicesAurora Cardiovascular and Thoracic ServicesAurora Cardiovascular and Thoracic ServicesAurora Cardiovascular and Thoracic ServicesAurora Cardiovascular and Thoracic ServicesObjective. To describe our institution’s experience with the AngioVac system. Background. Intracardiac and intravascular masses previously required surgical excision, but now, there are a number of minimally invasive options. With the advent of vacuum aspiration, more specifically the AngioVac System (AngioDynamics, NY, USA), there exists a system with both low mortality and minor complications. However, the number of retrospective studies remains limited. Outcome data for high-risk patients are also limited. Methods. Data were collected and analyzed in patients who underwent AngioVac therapy at our tertiary care center from January 2014 to December 2020. Results. Our results demonstrated a 93.3% intraoperative success rate and a 100% intraoperative survival rate. However, a number of complications, including but not limited to hematomas, anemia, and hypotension, occurred, as described below. Conclusions. Our experiences demonstrated good outcomes and continue to support the usefulness of the AngioVac System. The data also support the use of AngioVac as a treatment option for the debulking or removal of right heart masses in critically ill patients.http://dx.doi.org/10.1155/2021/9923440 |
| spellingShingle | Aashish Katapadi Lauren Richards William Fischer Suhail Q. Allaqaband Tanvir Bajwa M. Fuad Jan Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study Journal of Interventional Cardiology |
| title | Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study |
| title_full | Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study |
| title_fullStr | Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study |
| title_full_unstemmed | Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study |
| title_short | Endovascular Treatment of Right Heart Masses Utilizing the AngioVac System: A 6-Year Single-Center Observational Study |
| title_sort | endovascular treatment of right heart masses utilizing the angiovac system a 6 year single center observational study |
| url | http://dx.doi.org/10.1155/2021/9923440 |
| work_keys_str_mv | AT aashishkatapadi endovasculartreatmentofrightheartmassesutilizingtheangiovacsystema6yearsinglecenterobservationalstudy AT laurenrichards endovasculartreatmentofrightheartmassesutilizingtheangiovacsystema6yearsinglecenterobservationalstudy AT williamfischer endovasculartreatmentofrightheartmassesutilizingtheangiovacsystema6yearsinglecenterobservationalstudy AT suhailqallaqaband endovasculartreatmentofrightheartmassesutilizingtheangiovacsystema6yearsinglecenterobservationalstudy AT tanvirbajwa endovasculartreatmentofrightheartmassesutilizingtheangiovacsystema6yearsinglecenterobservationalstudy AT mfuadjan endovasculartreatmentofrightheartmassesutilizingtheangiovacsystema6yearsinglecenterobservationalstudy |